Oral miltefosine for Indian visceral leishmaniasis.
By S. Sundar, T. K. Jha, Thakur Cp, J. Engel, H. Sindermann, C. Fischer, K. Junge, A. Bryceson, J. Berman. New England Journal of Medicine, 2002
766 citations recorded by the source corpus.
Subfields: Parasitology, Public Health, Environmental and Occupational Health, Small Animals
View Paper: https://www.semanticscholar.org/paper/b8e3f53bb49db780f28c5109586cc9a750f4b393
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Public Health, Environmental and Occupational Health
Citations in the corpus
- Drug Resistance in Leishmaniasis (2006, unknown): “There has been increased use of amphotericin B for visceral leishmaniasis, in both the deoxycholate (142, 154) and lipid formulations (14, 143), following failure of antimonial treatment and in HIV/VL coinfection cases.”
- Drug resistance and treatment failure in leishmaniasis: A 21st century challenge (2017, methodology): “Since its registration in India in 2002, it has replaced the use of SSG as first-line treatment in the ISC [83,84], with cure rates higher than 94%.”
- The Relationship between Leishmaniasis and AIDS: the Second 10 Years (2008, background): “A study of 299 Indian patients showed that vomiting occurred in 38% and diarrhea occurred in 20% of patients and generally lasted 1 to 2 days (253); none of these patients were coinfected.”